89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
暂无分享,去创建一个
Serge K. Lyashchenko | M. Loda | S. Larson | V. Reuter | N. Bander | M. Gonen | M. Morris | H. Scher | Jason S. Lewis | S. Solomon | J. Durack | J. Carrasquillo | J. Osborne | W. Weber | P. Smith-Jones | N. Pandit-Taskar | J. Holland | S. Cheal | J. O’Donoghue | S. Ruan | R. Lefkowitz | V. Beylergil | S. Lyashchenko | Jason S. Lewis
[1] F. Bowman,et al. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. , 2014, The Journal of urology.
[2] V. Ambrosini,et al. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. , 2014, Clinical genitourinary cancer.
[3] Yongjun Yan,et al. A new 68Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging , 2014, Amino Acids.
[4] P. Choyke,et al. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. , 2014, Radiology.
[5] W. Schultze‐Seemann,et al. Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men , 2014, Theranostics.
[6] B. Hadaschik,et al. I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy , 2014 .
[7] T. Holland-Letz,et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[8] Steve Y. Cho,et al. Translational Molecular Imaging of Prostate Cancer , 2013, Current Radiology Reports.
[9] D. Rubello,et al. 11C-Choline PET/CT Scan in Patients With Prostate Cancer Treated With Intermittent ADT: A Sequential PET/CT Study , 2013, Clinical nuclear medicine.
[10] S. Larson,et al. Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? , 2013, Seminars in oncology.
[11] S. Larson,et al. 89Zr J591 immunoPET imaging in patients with prostate cancer , 2013 .
[12] A. Kibel,et al. 11C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction , 2013, The Journal of Nuclear Medicine.
[13] R. Dierckx,et al. Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer. , 2013, Molecular pharmaceutics.
[14] M. Picchio,et al. 11C-Choline PET/CT and PSA kinetics , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[15] U. Haberkorn,et al. PSMA as a target for radiolabelled small molecules , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[16] William C. Eckelman,et al. First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer , 2013, The Journal of Nuclear Medicine.
[17] J. Humm,et al. Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] George Sgouros,et al. Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer , 2012, The Journal of Nuclear Medicine.
[19] W. Oyen,et al. Prospects in radionuclide imaging of prostate cancer , 2012, The Prostate.
[20] Fan Wang,et al. Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer , 2012, Amino Acids.
[21] W. Oyen,et al. PET of Tumors Expressing Gastrin-Releasing Peptide Receptor with an 18F-Labeled Bombesin Analog , 2012, The Journal of Nuclear Medicine.
[22] T. Hoffman,et al. Bombesin analogues for gastrin-releasing peptide receptor imaging. , 2012, Nuclear medicine and biology.
[23] V. Ambrosini,et al. 11C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[24] F. Forrer,et al. Bombesin Antagonist–Based Radioligands for Translational Nuclear Imaging of Gastrin-Releasing Peptide Receptor–Positive Tumors , 2011, The Journal of Nuclear Medicine.
[25] W. Eckelman,et al. 123I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy , 2011, The Journal of Nuclear Medicine.
[26] E. Krenning,et al. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[27] S. Larson,et al. 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo , 2010, The Journal of Nuclear Medicine.
[28] P. Jurek,et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine , 2010, Nature Protocols.
[29] Ximing J. Yang,et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. , 2009, Human pathology.
[30] Jason S. Lewis,et al. Standardized methods for the production of high specific-activity zirconium-89. , 2009, Nuclear medicine and biology.
[31] S. Larson,et al. Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy , 2008, Journal of Nuclear Medicine.
[32] J. Votaw,et al. Biodistribution and Radiation Dosimetry of the Synthetic Nonmetabolized Amino Acid Analogue Anti-18F-FACBC in Humans , 2007, Journal of Nuclear Medicine.
[33] S. Larson,et al. Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors , 2007, Clinical Cancer Research.
[34] S. Larson,et al. Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer , 2005, Clinical Cancer Research.
[35] Michael G Stabin,et al. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[36] S. Vallabhajosula,et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] N. Bander,et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. , 2003, The Journal of urology.
[38] S. Vallabhajosula,et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. , 2003, The Journal of urology.
[39] N. Bander,et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. , 2003, Seminars in oncology.
[40] Y. Erdi,et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. , 2000, Medical physics.
[41] D. Bostwick,et al. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen , 1998, Cancer.
[42] N. Bander,et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. , 1998, Cancer research.
[43] D. Bostwick,et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma , 1998, Cancer.
[44] C Cobelli,et al. SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. , 1998, Metabolism: clinical and experimental.
[45] P. Bunn,et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.